Recent findings have shown that around 2–3% of NSCLC patients develop resistance to EGFR‐targeted therapies by undergoing histological transformation to small‐cell lung cancer (SCLC; Sequist et al, 2011). Here, EGFR is linked to small cell lung carcinoma.